VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Key findings of the LocoMMotion study

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares some insights into the LocoMMotion study (NCT04035226), which is evaluating treatment options for patients with relapsed/refractory (R/R) multiple myeloma who have been previously exposed to a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody (mAb). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter